Canaccord Genuity Reaffirms Buy Rating on Amarin Co. plc (AMRN)
Amarin Co. plc traded up 0.50% on Wednesday, hitting $11.6275. Amarin Co. plc has a 1-year low of $5.99 and a 1-year high of $19.87. The company’s market cap is $1.586 billion.
A number of other firms have also recently commented on AMRN. Analysts at Citigroup (NYSE: C) initiated coverage on shares of Amarin Co. plc in a research note to investors on Monday, April 30th. They set a “buy” rating and a $20.00 price target on the stock. Separately, analysts at JPMorgan Chase (NYSE: JPM) initiated coverage on shares of Amarin Co. plc in a research note to investors on Friday, April 20th. They set an “overweight” rating and a $22.00 price target on the stock. Finally, analysts at Jefferies Group (NYSE: JEF) reiterated a “positive” rating on shares of Amarin Co. plc in a research note to investors on Wednesday, March 28th.
Amarin Corporation plc (Amarin) is a clinical-stage biopharmaceutical company focused on developing improved treatments for cardiovascular disease.